Universal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH purchased 8,676 shares of LeMaitre Vascular, Inc. for approximately $728,000, indicating strong institutional interest in the medical instruments supplier.
• LeMaitre Vascular stock is currently rated as a "Hold" by five analysts, with an average price target of $97.83, reflecting cautious investor sentiment.
• The company reported $0.48 earnings per share for the latest quarter, missing estimates but achieved revenue of $59.87 million, which was above analyst forecasts.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,676 shares of the medical instruments supplier's stock, valued at approximately $728,000.

Several other institutional investors and hedge funds have also bought and sold shares of LMAT. JPMorgan Chase & Co. boosted its holdings in shares of LeMaitre Vascular by 45.9% in the 4th quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier's stock valued at $13,590,000 after purchasing an additional 46,430 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of LeMaitre Vascular by 239.5% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 9,833 shares of the medical instruments supplier's stock worth $906,000 after buying an additional 6,937 shares during the last quarter. Alliancebernstein L.P. boosted its stake in LeMaitre Vascular by 6.0% in the fourth quarter. Alliancebernstein L.P. now owns 22,584 shares of the medical instruments supplier's stock valued at $2,081,000 after buying an additional 1,287 shares in the last quarter. Franklin Resources Inc. grew its position in LeMaitre Vascular by 8.2% in the fourth quarter. Franklin Resources Inc. now owns 13,678 shares of the medical instruments supplier's stock valued at $1,260,000 after acquiring an additional 1,032 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in LeMaitre Vascular by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock worth $50,711,000 after acquiring an additional 7,737 shares in the last quarter. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Trading Up 8.5%

LMAT stock traded up $7.27 during trading on Wednesday, reaching $92.87. The company had a trading volume of 271,291 shares, compared to its average volume of 188,119. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The company has a market cap of $2.10 billion, a P/E ratio of 46.90, a PEG ratio of 2.23 and a beta of 0.79. The business has a 50 day moving average of $82.64 and a 200 day moving average of $86.68. The company has a debt-to-equity ratio of 0.48, a current ratio of 16.49 and a quick ratio of 13.83.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. The firm had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. During the same period last year, the business posted $0.52 EPS. The company's revenue for the quarter was up 15.0% on a year-over-year basis. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 4,399 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total value of $374,354.90. Following the completion of the transaction, the chief executive officer directly owned 1,827,003 shares in the company, valued at approximately $155,477,955.30. The trade was a 0.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 100,000 shares of company stock valued at $8,556,857 in the last quarter. Corporate insiders own 9.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on LMAT. Cantor Fitzgerald raised their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research note on Wednesday. Barrington Research upgraded LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, LeMaitre Vascular currently has a consensus rating of "Hold" and an average target price of $98.00.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.